AssetMemo
AssetsMechanismsCompaniesCalendarChartsWatchlistAsk AIMethodology
  • Cardiovascular & Metabolic469
  • Dermatology230
  • Gastroenterology & Hepatology177
  • Hematology45
  • Immunology176
  • Infectious Disease145
  • Nephrology130
  • Neurology478
  • Oncology1,186
  • Ophthalmology75
  • Psychiatry141
  • Rare & Genetic Diseases141
  • Respiratory162
◧AssetMemo
⌕

Evidence-graded drug-asset intelligence
◧AssetMemo
AssetsMechanismsCompaniesReadout CalendarCompare ChartsWatchlist & AlertsAsk AI
Therapeutic areas
  • Cardiovascular & Metabolic469
  • Dermatology230
  • Gastroenterology & Hepatology177
  • Hematology45
  • Immunology176
  • Infectious Disease145
  • Nephrology130
  • Neurology478
  • Oncology1,186
  • Ophthalmology75
  • Psychiatry141
  • Rare & Genetic Diseases141
  • Respiratory162
ReferenceMethodology & RubricUs vs. AI ToolsUK IBD Access GuideAbout the founder

Educational data tool. Evidence graded; securities never are.

BrowseAll assetsAll mechanismsAll companiesReadout calendarReadouts by yearResults by diseaseDelayed readoutsOpen dataCompare share pricesWhat's new
ReferenceMethodology & sourcesUs vs. the AI toolsUK IBD Access GuideAbout the founderAsk the AIReport a problem / suggest a feature

Educational research only, not investment advice. Evidence quality is graded; securities never are. · Terms · Privacy · Logos by Logo.dev

Ask

Opening the console…

1,457 drug developers and their pipelines

Start from a saved view, or filter by area, exchange and headquarters. Each row shows the pipeline, its most advanced asset and the next readout on record.

Lists by late-stage drug kind: biologics, small molecules, cell and gene therapies, RNA and oligonucleotide drugs, peptide drugs.

← browse by therapeutic area

Views

1457 of 1457 companies

CompanyPipelineMost advancedNext readoutMarket capCash & inv.RunwayR&D / yr
Luye Pharma Group logo
Luye Pharma Group2186 · HKEX
12 assets: 4 approved, 4 Ph 3, 2 Ph 2, 2 Ph 1Ansofaxine hydrochloridePhase 3 · Major Depressive DisorderReliable signal28 Feb 2027Ansofaxine hydrochloride · Approved———$260M
Mabwell Bioscience logo
Mabwell Bioscience688062 · SSE STAR Market
3 assets: 2 Ph 3, 1 Ph 27MW3711Phase 3 · Non-Small Cell Lung CancerDec 20279MW1911 · Phase 2———~$95M
Mayne Pharma logo
Mayne PharmaMYX · ASX
2 assets: 2 approvedApproved assets onlyNone on record————
Medicenna Therapeutics, Inc. logo
Medicenna Therapeutics, Inc.MDNA · TSX
2 assets: 2 Ph 2bizaxofuspPhase 2 · Recurrent Glioblastoma20 Oct 2028MDNA11 · Phase 1/2————
Medincell logo
MedincellMEDCL · Euronext Paris
2 assets: 2 approvedApproved assets onlyNone on record————
Medivir AB logo
Medivir ABMVIR · Nasdaq Stockholm
1 asset: 1 Ph 2BirinapantPhase 2 · Ovarian CancerNone on record————
MeiraGTx Limited logo
MeiraGTx LimitedMGTX · Nasdaq
1 asset: 1 Ph 2AAV-GAD gene therapyPhase 2 · Parkinson's DiseaseWeak signalOct 2029AAV-GAD gene therapy · Phase 1/2—$187MSep 2026Cash-flow positive$160M
Mendus logo
MendusIMMU · Nasdaq Stockholm
1 asset: 1 Ph 2VididencelPhase 2 · Acute Myeloid LeukemiaWeak signal1 Sep 2029Vididencel · Phase 1—$7.0MDec 2025Ended May 2026~-$9.1M
Merck KGaA logo
Merck KGaAMKKGY · OTC
8 assets: 7 approved, 1 Ph 3precemtabart tocentecanPhase 3 · Metastatic Colorectal CancerApr 2027Cetuximab · Phase 1/2—no price since 18 Aug 2026—Profitable—
M
Mezzion Pharma140410 · KOSDAQ
1 asset: 1 Ph 3UdenafilPhase 2/3 · Pulmonary Arterial HypertensionWeak signalNone on record————
Molecular Partners logo
Molecular PartnersMOLN ·
2 assets: 2 Ph 1MP0310Phase 1 · Advanced Solid TumorsNone on record—$117MDec 2025~7.6 qtrs$48M
Nanjing Leads Biolabs Co.,Ltd logo
Nanjing Leads Biolabs Co.,Ltd9887 · HKEX
3 assets: 2 Ph 2, 1 Ph 1OpamtistomigPhase 2 · Non-Small Cell Lung CancerDec 2026Opamtistomig · Phase 1/2—$59MMar 2025Ended Sep 2026~$32M
Nanobiotix logo
NanobiotixNBTX · Nasdaq
1 asset: 1 Ph 3NBTXR3Phase 3 · Head and Neck Squamous Cell Carcinoma30 Apr 2027NBTXR3 · Phase 1—$62MDec 2025~6.5 qtrs$26M
Nature Cell Co., Ltd. logo
Nature Cell Co., Ltd.007390 · KOSDAQ
1 asset: 1 Ph 2AstroStemPhase 2 · Alzheimer's DiseasePartial signalNone on record————
Neuren Pharmaceuticals logo
Neuren PharmaceuticalsNEU · ASX
1 asset: 1 approvedApproved assets onlyNone on record————
Newron Sweden AB logo
Newron Sweden ABPrivate
1 asset: 1 otherTelberminDiscontinuedNone on record————
Nippon Kayaku logo
Nippon Kayaku4272 · TSE
2 assets: 1 approved, 1 Ph 2DarinaparsinPhase 2 · Peripheral T-Cell LymphomaWeak signal2 Feb 2027Taletrectinib · Phase 1————
Nippon Shinyaku logo
Nippon Shinyaku4516 · TSE
6 assets: 4 approved, 2 Ph 3Clemidsogene lanparvovecPhase 3 · Mucopolysaccharidosis Type II30 Apr 2027Ferric derisomaltose · Phase 3————
NKGen Biotech logo
NKGen BiotechNKGN · OTC
1 asset: 1 Ph 2TroculeucelPhase 1/2 · Alzheimer's DiseaseWeak signalMar 2028Troculeucel · Phase 1/2—no price since 18 Aug 2026<$0.1MMar 2025Ended Mar 2025$9.3M
N
Nova Pneuma Inc.Private
1 asset: 1 Ph 3Staccato AlprazolamPhase 3 · EpilepsyReliable signal29 Mar 2027Staccato Alprazolam · Phase 3————
Nxera Pharma logo
Nxera Pharma4565 · TSE
1 asset: 1 Ph 3DireclidinePhase 3 · SchizophreniaPartial signalOct 2027Direclidine · Phase 3————
Obsidian Therapeutics, Inc. logo
Obsidian Therapeutics, Inc.OBX · Nasdaq
1 asset: 1 Ph 2OBX-115Phase 1/2 · Non-Small Cell Lung Cancer30 Jun 2029OBX-115 · Phase 1/2—$216MSep 2026~11.2 qtrs$89M
Oneness Biotech logo
Oneness Biotech4743 · TPEx
1 asset: 1 Ph 2FB825Phase 2 · Atopic DermatitisWeak signal31 May 2027FB825 · Phase 2————
Ono Pharmaceutical logo
Ono Pharmaceutical4528 · TSE
16 assets: 11 approved, 1 Ph 3, 2 Ph 2, 2 Ph 1ONO-4578Phase 3 · Gastric CancerReliable signal10 Dec 2026Dapagliflozin · Phase 2—$1.5BMar 2026—$969M
Organon logo
OrganonOGN · NYSE
12 assets: 11 approved, 1 otherAtozet (ezetimibe/atorvastatin)Atherosclerotic Cardiovascular DiseaseAug 2027Tapinarof · Phase 3—$1.5BSep 2026Cash-flow positive$357M
O
Orient EuroPharma4120 · TPEx
1 asset: 1 approvedApproved assets onlyNone on record————
Orion Corporation logo
Orion CorporationORNBV · Nasdaq Helsinki
2 assets: 1 approved, 1 Ph 3LevosimendanPhase 3 · Heart FailurePartial signal30 Jun 2028Levosimendan · Phase 3—$189MDec 2025—$239M
Oryzon Genomics, S.A. logo
Oryzon Genomics, S.A.ORY · BME
1 asset: 1 Ph 2IadademstatPhase 2 · Acute Myeloid LeukemiaWeak signalNone on record—$33MDec 2025~8.3 qtrs$14M
Oscotec Inc. logo
Oscotec Inc.039200 · KOSDAQ
1 asset: 1 Ph 1OCT-598Phase 1 · Non-Small Cell Lung CancerDec 2027OCT-598 · Phase 1————
OSE Immunotherapeutics logo
OSE ImmunotherapeuticsOSE · Euronext Paris
2 assets: 1 Ph 3, 1 Ph 2OSE2101Phase 3 · Non-Small Cell Lung CancerPartial signal1 May 2028OSE2101 · Phase 3————
Otsuka Holdings logo
Otsuka Holdings4578 · TSE
23 assets: 15 approved, 4 Ph 3, 2 Ph 2, 2 Ph 1UlefnersenPhase 3 · Amyotrophic Lateral SclerosisReliable signalDec 2026Donidalorsen · Phase 3—$3.4BMar 2026—~$2.1B
Parataxis Korea, Inc. logo
Parataxis Korea, Inc.288330 · KOSDAQ
1 asset: 1 Ph 2BBT-207Phase 1/2 · Non-Small Cell Lung CancerNone on record————
PegBio logo
PegBio2565 · HKEX
3 assets: 2 Ph 3, 1 Ph 2Visepegenatide (PB-119)Phase 3 · Type 2 DiabetesReliable signalNone on record————
Peptron logo
Peptron087010 · KOSDAQ
1 asset: 1 Ph 2Exenatide (PT320)Phase 2 · Parkinson's DiseasePartial signalNone on record————
PharmaEngine logo
PharmaEngine4162 · TPEx
1 asset: 1 Ph 1PEP07Phase 1 · Acute Myeloid Leukemia31 Dec 2026PEP07 · Phase 1————
P
PharmaEssentia Corporation6446 · TWSE
1 asset: 1 approvedApproved assets only18 Nov 2027Ropeginterferon alfa-2b (Besremi) · Phase 3————
PharmaMar logo
PharmaMarPHM · BME
2 assets: 1 approved, 1 Ph 3PlitidepsinPhase 3 · Multiple MyelomaPartial signal31 Dec 2027Lurbinectedin · Phase 3————
Pharmosa Biopharm Inc. logo
Pharmosa Biopharm Inc.6875 · TPEx
1 asset: 1 Ph 3Treprostinil (L606)Phase 3 · Pulmonary Arterial HypertensionJul 2029Treprostinil (L606) · Phase 3————
Pila Pharma logo
Pila PharmaPILA · Nasdaq First North
1 asset: 1 Ph 2XEN-D0501Phase 2 · Type 2 DiabetesPartial signalNone on record—$1.7MDec 2025Ended Apr 2026—
Polaris Group logo
Polaris Group6550 · TWSE
1 asset: 1 Ph 3PegargiminasePhase 3 · Hepatocellular CarcinomaWeak signalJan 2027Pegargiminase · Phase 1————
Prestige Biopharma Limited logo
Prestige Biopharma Limited950210 · KOSPI
1 asset: 1 Ph 3HD204Phase 3 · Non-Small Cell Lung CancerReliable signalNone on record————
ProGen logo
ProGen296160 · KONEX
2 assets: 1 Ph 2, 1 Ph 1PG-102Phase 2 · ObesityPartial signal1 Dec 2026RT-114 · Phase 1————
ProPhase Labs, Inc. (formerly The Quigley Corporation) logo
ProPhase Labs, Inc. (formerly The Quigley Corporation)PRPH · OTC
1 asset: 1 otherLinebackerSolid TumorsNone on record—no price since 18 Aug 2026<$0.1MJun 2026Ended Jul 2026$0.1M
Prothena Biosciences Limited logo
Prothena Biosciences LimitedPRTA · Nasdaq
2 assets: 1 Ph 3, 1 Ph 2PrasinezumabPhase 3 · Parkinson's Disease17 Dec 2026Moponetug · Phase 2—$272MSep 2026~9.6 qtrs$83M
Provectus Pharmaceuticals logo
Provectus PharmaceuticalsPVCT · OTC
2 assets: 1 Ph 3, 1 Ph 2rose bengal disodiumPhase 3 · Locally Advanced Cutaneous MelanomaNone on record—no price since 18 Aug 2026—~1.9 qtrsJun 2026$1.0M
PureTech Health logo
PureTech HealthPTCHF · OTC
2 assets: 2 Ph 2GlyphAllo (allopregnanolone prodrug)Phase 2 · Major Depressive DisorderMar 2027GlyphAllo (allopregnanolone prodrug) · Phase 2—no price since 18 Aug 2026$281MDec 2024~8.4 qtrs$69M
Quince Therapeutics logo
Quince TherapeuticsQNCX · Nasdaq
1 asset: 1 Ph 2LAM-001Phase 2 · Pulmonary Hypertension Associated with Interstitial Lung DiseaseNone on record—no price since 9 Oct 2026$105MSep 2026~8.6 qtrs$31M
Q
Qyuns Therapeutics2509 · HKEX
1 asset: 1 Ph 3HS-20137Phase 3 · Psoriasis1 Mar 2027HS-20137 · Phase 2————
Radiopharm Theranostics, Ltd logo
Radiopharm Theranostics, LtdRADX · Nasdaq
4 assets: 2 Ph 2, 2 Ph 1RAD101Phase 2 · Brain MetastasesDec 2027RAD202 · Phase 1—$29MJun 2025Ended May 2026with a later raise$28M
Recordati logo
RecordatiREC · Euronext Milan
4 assets: 3 approved, 1 otherLercanidipineHypertensionNone on record————
REGENXBIO Inc. logo
REGENXBIO Inc.RGNX · Nasdaq
3 assets: 3 Ph 3Surabgene lomparvovecPhase 3 · Age-Related Macular DegenerationWeak signalDec 2026Surabgene lomparvovec · Phase 2/3—$251MSep 2026~6.6 qtrs$234M
RemeGen Co., Ltd. logo
RemeGen Co., Ltd.688331 · SSE
6 assets: 4 Ph 3, 1 Ph 2, 1 Ph 1TelitaciceptPhase 3 · Rheumatoid ArthritisReliable signalDec 2026Disitamab Vedotin · Phase 2/3—$213MDec 2025—$170M
Roche logo
RocheRHHBY · OTC
68 assets: 23 approved, 20 Ph 3, 7 Ph 2, 4 Ph 1, 14 otherastegolimabPhase 3 · Chronic Obstructive Pulmonary DiseaseReliable signalNov 2026Venetoclax · Phase 2—no price since 18 Aug 2026——$14.7B
Rohto Pharmaceutical logo
Rohto Pharmaceutical4527 · TSE
1 asset: 1 Ph 2ADR-002KPhase 2 · Heart Failure30 Sep 2028ADR-002K · Phase 2—$522MMar 2026—$91M
Roivant Sciences Ltd. logo
Roivant Sciences Ltd.ROIV · Nasdaq
3 assets: 1 approved, 2 Ph 3ImeroprubartPhase 3 · Myasthenia GravisDec 2026Mosliciguat · Phase 2—$4.2BSep 202610+ years~$678M
Ryvu Therapeutics SA logo
Ryvu Therapeutics SARVU · GPW
1 asset: 1 Ph 2RomaciclibPhase 2 · Acute Myeloid LeukemiaWeak signalDec 2026Romaciclib · Phase 2—$17MDec 2025Ended Mar 2026$48M
S.Biomedics logo
S.Biomedics304360 · KOSDAQ
2 assets: 2 Ph 2Adipose-derived MSC clusters (S.Biomedics)Phase 1/2 · Atherosclerotic Cardiovascular DiseaseWeak signal7 Feb 2029TED-A9 (A9-DPC) · Phase na————
Sagimet Biosciences Inc. logo
Sagimet Biosciences Inc.SGMT · Nasdaq
1 asset: 1 Ph 3DenifanstatPhase 3 · Recurrent GlioblastomaReliable signalAug 2027Denifanstat · Phase 3—$236MSep 2026~31.5 qtrswith a later raise$42M
Sam Chun Dang Pharm. Co., Ltd. logo
Sam Chun Dang Pharm. Co., Ltd.000250 · KOSDAQ
1 asset: 1 otherAflibercept (Vgenfli)Age-Related Macular DegenerationNone on record————
Sandoz Group AG logo
Sandoz Group AGSDZ · SIX
9 assets: 9 approvedApproved assets onlyNone on record————
Sangamo Therapeutics logo
Sangamo TherapeuticsSGMOQ · OTC
1 asset: 1 Ph 2TX200Phase 1/2 · Kidney Transplant Rejection ProphylaxisNone on record—no price since 18 Aug 2026$28MMar 2026Ended Jul 2026$113M
Saniona logo
SanionaSANION · Nasdaq Stockholm
1 asset: 1 Ph 3TesofensinePhase 3 · ObesityReliable signalNone on record—$63MDec 2025~12.8 qtrs—
Santen Pharmaceutical Co., Ltd. logo
Santen Pharmaceutical Co., Ltd.4536 · TSE
1 asset: 1 Ph 3RC28-EPhase 3 · Age-Related Macular DegenerationPartial signal1 Dec 2028RC28-E · Phase 3————
Scilex Pharmaceuticals logo
Scilex PharmaceuticalsPrivate
1 asset: 1 approvedApproved assets onlyNone on record————
SCM Lifescience logo
SCM Lifescience298060 · KOSDAQ
1 asset: 1 Ph 2SCM-AGHPhase 1/2 · Atopic DermatitisPartial signalNone on record————
Shaanxi Micot Pharmaceutical Technology logo
Shaanxi Micot Pharmaceutical Technology2335 · HKEX
1 asset: 1 Ph 3MT1013Phase 3 · Chronic Kidney DiseasePartial signal26 Nov 2026MT1013 · Phase 3———~$11M
Shandong Boan Biotechnology Co., Ltd logo
Shandong Boan Biotechnology Co., Ltd6955 · HKEX
1 asset: 1 Ph 1BA1302Phase 1 · Non-Small Cell Lung Cancer31 Dec 2027BA1302 · Phase 1———$11M
Shanghai Bao Pharmaceuticals Co., Ltd. logo
Shanghai Bao Pharmaceuticals Co., Ltd.2659 · HKEX
1 asset: 1 Ph 1KJ015Phase 1 · Non-Small Cell Lung Cancer31 Dec 2026KJ015 · Phase 1————
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. logo
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.600196 · SSE
2 assets: 2 Ph 3AR1001Phase 3 · Alzheimer's DiseasePartial signal12 May 2027Velinotamig (GR1803) · Phase 2————
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. logo
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.600196 · SSE
10 assets: 2 approved, 3 Ph 3, 3 Ph 2, 2 Ph 1SerplulimabPhase 3 · Non-Small Cell Lung CancerReliable signal1 Dec 2026FCN-338 · Phase 2————
Shanghai Henlius Biotech logo
Shanghai Henlius Biotech2696 · HKEX
14 assets: 8 Ph 3, 4 Ph 2, 2 Ph 1HLX01Phase 3 · Rheumatoid ArthritisReliable signal22 Nov 2026HLX43 · Phase 2———$347M
Shanghai Junshi Bioscience logo
Shanghai Junshi Bioscience1877 · HKEX
8 assets: 1 approved, 4 Ph 3, 2 Ph 2, 1 Ph 1OngericimabPhase 3 · Atherosclerotic Cardiovascular DiseaseReliable signal27 Nov 2026JS207 · Phase 2—$456MDec 2025~3.7 qtrs$193M
S
Shanghai Pharmaceuticals Holding2607 · SSE
2 assets: 1 Ph 3, 1 Ph 2SPH4336Phase 2/3 · HR+/HER2- Metastatic Breast Cancer1 Dec 2026SPH4336 · Phase 2/3—$4.8BDec 2025—$345M
Shaperon logo
Shaperon378800 · KOSDAQ
1 asset: 1 Ph 2HY209gelPhase 2 · Atopic DermatitisPartial signalNone on record————
Shenzhen Salubris Pharmaceuticals logo
Shenzhen Salubris Pharmaceuticals002294 · SZSE
7 assets: 3 Ph 3, 4 Ph 2EnarodustatPhase 3 · Chronic Kidney DiseaseReliable signal12 Dec 2026SAL0137 · Phase 2—$157MMar 2026—$79M
Shijiazhuang Yiling Pharmaceutical Co. Ltd logo
Shijiazhuang Yiling Pharmaceutical Co. Ltd002603 · SZSE
1 asset: 1 Ph 3XY0206Phase 3 · Acute Myeloid Leukemia1 Jul 2027XY0206 · Phase 3————
S
Shin Nippon Biomedical Laboratories2395 · TSE
1 asset: 1 approvedApproved assets onlyNone on record————
Shionogi logo
Shionogi4507 · TSE
7 assets: 5 approved, 2 Ph 3EnarodustatPhase 3 · Chronic Kidney DiseaseReliable signal25 Jan 2027Rosuvastatin · Phase 1—$4.5BMar 2026—$810M
Sichuan Baili Pharmaceutical logo
Sichuan Baili Pharmaceutical688506 · SSE STAR Market
9 assets: 3 Ph 3, 4 Ph 2, 2 Ph 1IzalontamabPhase 3 · Non-Small Cell Lung CancerNov 2026Izalontamab brengitecan · Phase 3—$430MMar 2026—$350M
Sichuan Huiyu Pharmaceutical Co., Ltd logo
Sichuan Huiyu Pharmaceutical Co., Ltd688553 · SSE STAR Market
1 asset: 1 Ph 2HYP-6589Phase 1/2 · Non-Small Cell Lung Cancer10 Apr 2028HYP-6589 · Phase 1/2————
Sichuan Kelun Pharmaceutical Co., Ltd. logo
Sichuan Kelun Pharmaceutical Co., Ltd.002422 · SZSE
1 asset: 1 Ph 1Brexpiprazole long-acting injection (Kelun)Phase 1 · SchizophreniaNone on record————
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. logo
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.6990 · HKEX
7 assets: 3 Ph 3, 3 Ph 2, 1 Ph 1Sacituzumab TirumotecanPhase 3 · Non-Small Cell Lung CancerPartial signalNov 2026Sacituzumab Tirumotecan · Phase 3—$651MDec 2025~12.2 qtrs$184M
Sihuan Pharmaceutical Holdings logo
Sihuan Pharmaceutical Holdings0460 · HKEX
1 asset: 1 Ph 3janagliflozinPhase 3 · Type 2 DiabetesReliable signal31 Dec 2027janagliflozin · Approved—$509MDec 2025—$41M
SillaJen, Inc. logo
SillaJen, Inc.215600 · KOSDAQ
1 asset: 1 Ph 1BAL0891Phase 1 · Acute Myeloid Leukemia24 Dec 2026BAL0891 · Phase 1—$3.7MDec 2025—$11M
Simcere Pharmaceutical logo
Simcere Pharmaceutical2096 · HKEX
9 assets: 7 Ph 3, 2 Ph 1ZemprocitinibPhase 3 · Atopic DermatitisReliable signalNov 2026Zemprocitinib · Phase 3——Profitable—
Sino Biopharmaceutical logo
Sino Biopharmaceutical1177 · HKEX
16 assets: 1 approved, 7 Ph 3, 4 Ph 2, 4 Ph 1CulmerciclibPhase 3 · HR+/HER2- Metastatic Breast CancerPartial signalDec 2026Culmerciclib · Phase 3—$1.8BDec 2025—$866M
Sinocelltech Group Ltd. logo
Sinocelltech Group Ltd.688520 · SSE
3 assets: 3 Ph 3SCTB14Phase 3 · Non-Small Cell Lung CancerApr 2027SCTC21C · Phase 1/2———$118M
SinoMab BioScience logo
SinoMab BioScience3681 · HKEX
1 asset: 1 Ph 2SM17Phase 2 · Atopic DermatitisWeak signal25 Apr 2027SM17 · Phase 2————
SK Biopharmaceuticals Co., Ltd. logo
SK Biopharmaceuticals Co., Ltd.326030 · KOSPI
3 assets: 2 approved, 1 Ph 3CarisbamatePhase 3 · EpilepsyPartial signalDec 2026Solriamfetol · Phase 3————
SK Chemicals logo
SK Chemicals285130 · KOSPI
1 asset: 1 othercilostazol/Ginkgo bilobaAtherosclerotic Cardiovascular DiseaseNone on record—$393MDec 2025——
SNLD, Ltd. logo
SNLD, Ltd.Private
2 assets: 1 Ph 2, 1 Ph 1TR-012001Phase 2 · Parkinson's DiseaseWeak signalNone on record————
Solasia Pharma K.K. logo
Solasia Pharma K.K.4597 · TSE
1 asset: 1 Ph 2DarinaparsinPhase 2 · Peripheral T-Cell LymphomaWeak signalNone on record————
S
SPIMACOPrivate
1 asset: 1 approvedApproved assets onlyMay 2027Lovotibeglogene autotemcel (Lyfgenia) · Phase 3————
STCube, Inc. logo
STCube, Inc.052020 · KOSDAQ
1 asset: 1 Ph 2NelmastobartPhase 2 · Non-Small Cell Lung Cancer31 Aug 2027Nelmastobart · Phase 2————
Sumitomo Pharma logo
Sumitomo Pharma4506 · TSE
7 assets: 3 approved, 1 Ph 3, 3 Ph 2VildagliptinPhase 3 · Type 2 DiabetesPartial signal30 Jun 2027Enzomenib · Phase 1/2———$289M
Summit Therapeutics logo
Summit TherapeuticsSMMT · Nasdaq
1 asset: 1 Ph 3IvonescimabPhase 3 · Non-Small Cell Lung CancerReliable signalDec 2026Ivonescimab · Phase 3—$630MSep 2026~4.8 qtrs$80M
Sun Pharma Advanced Research Company Limited logo
Sun Pharma Advanced Research Company LimitedSPARC · NSE
1 asset: 1 approvedApproved assets onlyNone on record————
Sun Pharmaceutical Industries logo
Sun Pharmaceutical IndustriesSUNPHARMA · NSE
6 assets: 4 approved, 1 Ph 3, 1 Ph 2LerodalcibepPhase 3 · Atherosclerotic Cardiovascular DiseaseReliable signalApr 2027Utreglutide · Phase 2—$1.0BMar 2026Profitable$401M
Sunho Biologics logo
Sunho Biologics2898 · HKEX
2 assets: 1 Ph 2, 1 Ph 1IAP0971Phase 1/2 · Non-Small Cell Lung Cancer28 Feb 2027ISH0688 · Phase 1—$24MJun 2025Ended Aug 2026—
Sunshine Guojian Pharmaceutical logo
Sunshine Guojian Pharmaceutical688336 · SSE STAR Market
3 assets: 2 Ph 3, 1 Ph 2Amdokitug (Yisaituo)Phase 3 · Psoriasis14 Jan 2027Amdokitug (Yisaituo) · Phase 3—$243MDec 2025Profitable—

Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov). Cash shows its balance-sheet month; runway shows a month only when it comes from an earlier report.

Page123456789101112131415